Document and Entity Information
Document and Entity Information | Jul. 12, 2021 |
Cover [Abstract] | |
Document Type | 8-K/A |
Document Period End Date | Jul. 12, 2021 |
Entity Registrant Name | TEMPEST THERAPEUTICS, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-35890 |
Entity Tax Identification Number | 45-1472564 |
Entity Address, Address Line One | 7000 Shoreline Court |
Entity Address, Address Line Two | Suite 275 |
Entity Address, City or Town | South San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94080 |
City Area Code | 415 |
Local Phone Number | 798-8589 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | TPST |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | This Amendment No. 1 to Current Report on Form 8-K/A (the “8-K Amendment”) is being filed to amend the Current Report on Form 8-K of Tempest Therapeutics, Inc. (the “Company”) filed on July 12, 2021 (the “Original 8-K”). The Original 8-K included disclosure in Item 5.02 with respect to the appointment of Nicholas Maestas as vice president, strategy and finance and is the Company’s principal financial officer. This 8-K Amendment supplements and amends Item 5.02 to include a correction to a clerical error in the original filing, of which the Company became aware after the filing of the Original 8-K, with respect to the terms of the option grant made to Mr. Maestas. |
Amendment Flag | true |
Entity Central Index Key | 0001544227 |